Skip to main content

ADCETRIS (Takeda Pharmaceuticals Australia Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
188 (255 working days)
Active ingredients
Brentuximab vedotin
Registration type

Hodgkin lymphoma

Treatment of patients with previously untreated CD30+ Stage III or Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD).

Help us improve the Therapeutic Goods Administration site